A randomized, open-label trial of edoxaban in Japanese patients with severe renal impairment undergoing lower-limb orthopedic surgery

BACKGROUND: Edoxaban is an oral, direct, factor Xa inhibitor approved in Japan for thromboembolic prophylaxis after lower-limb orthopedic surgery (LLOS), but contraindicated in patients with severe renal impairment (SRI; creatinine clearance [CL(CR)] ≥15 to <30 mL/min). METHODS: This open-label s...

Descripción completa

Detalles Bibliográficos
Autores principales: Fuji, Takeshi, Fujita, Satoru, Kawai, Yohko, Abe, Yasuyuki, Kimura, Tetsuya, Fukuzawa, Masayuki, Abe, Kenji, Tachibana, Shintaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Original Clinical Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4316611/
https://www.ncbi.nlm.nih.gov/pubmed/25653574
http://dx.doi.org/10.1186/s12959-014-0034-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4316611/
https://www.ncbi.nlm.nih.gov/pubmed/25653574
http://dx.doi.org/10.1186/s12959-014-0034-9

Ejemplares similares